Advertise on podcast: Research To Practice | Oncology Videos

Featuring perspectives from Dr Catherine C Coombs, including the following topics: Early versus delayed addition of obinutuzumab to acalabrutinib and venetoclax in treatment-naïve chronic lymphocytic leukemia (CLL) (0:00) Feasibility of discontinuation of Bruton tyrosine kinase (BTK) inhibitor therapy in CLL; minimal residual disease and disease monitoring (4:10) Ongoing Phase III trials of BTK inhibitor/B-cell lymphoma 2 inhibitor combinations in previously untreated CLL (10:05) Pirtobrutinib as first-line therapy for CLL and long-term safety data (15:22) CME information and select publications

Featuring perspectives from Dr Nicoletta Colombo, Dr Gottfried E Konecny, Dr Alexander B Olawaiye and Dr Shannon N Westin, moderated by Dr Westin, including the following topics: Case: A woman in her mid 50s with BRCA1-mutated recurrent ovarian cancer receives mirvetuximab soravtansine — Ursula Matulonis, MD (0:00) CME information and select publications

Featuring perspectives from Dr Nicoletta Colombo, Dr Gottfried E Konecny, Dr Alexander B Olawaiye and Dr Shannon N Westin, moderated by Dr Westin, including the following topics: Case: A woman in her early 50s with a germline BRCA1 mutation and ovarian cancer experiences disease recurrence after completing olaparib/bevacizumab maintenance therapy — Professor Jonathan A Ledermann (0:00) CME information and select publications

Featuring perspectives from Dr Meletios-Athanasios (Thanos) C Dimopoulos, Dr Robert Z Orlowski and Dr Noopur Raje, moderated by Dr Orlowski, including the following topics: Introduction (0:00) New and Emerging Strategies with Bispecific Antibodies in Multiple Myeloma (MM) — Dr Raje (2:20) Utility of Antibody-Drug Conjugates for Relapsed/Refractory (R/R) MM — Dr Orlowski (23:33) Potential Role of Cereblon E3 Ligase Modulators and Other Promising Novel Agents and Strategies for R/R MM — Prof Dimopoulos (41:12) CME information and select publications

Featuring perspectives from Dr Sara M Tolaney, including the following topics: Management of adverse events associated with TROP2-targeting antibody-drug conjugates (0:00) Managing brain metastases in triple-negative breast cancer (6:30) EGFR x HER3-directed bispecific antibodies for metastatic triple-negative breast cancer (mTNBC) (9:11) PD-1/PD-L1 x VEGF-directed bispecific antibodies for mTNBC (12:31) CME information and select publications

Featuring perspectives from Dr Sara M Tolaney, including the following topics: Mechanistic effects and potential resistance mechanisms of antibody-drug conjugates (0:00) First-line treatment of metastatic triple-negative breast cancer (mTNBC) in patients eligible for immunotherapy (7:13) First-line treatment of mTNBC in patients ineligible for immunotherapy (13:02) Antibody-drug conjugates for previously treated HER2-low metastatic breast cancer (19:15) CME information and select publications

Featuring perspectives from Dr Catherine C Coombs and Dr Matthew S Davids, including the following topics: Introduction (0:00) Minimal Residual Disease Assays in Community-Based Practice (1:24) New Developments in Previously Untreated Chronic Lymphocytic Leukemia (CLL) — Dr Davids (8:12) Richter Transformation (30:43) Selection and Sequencing of Therapies for Relapsed/Refractory CLL — Dr Coombs (34:49) CME information and select publications

Featuring perspectives from Dr Joyce F Liu, Dr David M O'Malley and Dr Brian M Slomovitz, moderated by Dr O'Malley, including the following topics: Case: A woman in her mid 60s with Stage II uterine carcinosarcoma treated with surgery followed by paclitaxel/carboplatin, whole-pelvic radiation and vaginal cuff brachytherapy — Dr Angeles Alvarez Secord (0:00) Case: A woman in her mid 50s with ovarian cancer and a genomic instability score of 50, folate receptor alpha 90%, HER2 IHC 2+, and BRCA1/2 wild-type disease treated initially with surgery, carboplatin/paclitaxel and maintenance olaparib/bevacizumab — Dr Ursula Matulonis (8:46) CME information and select publications

Featuring an interview with Dr L Elizabeth Budde, including the following topics: Considerations for selecting between bispecific antibodies (BsAbs); monotherapy versus combination therapy (0:00) Management of BsAb-induced cytokine release syndrome and other toxicities (7:35) Use of BsAbs in the front-line treatment of diffuse large B-cell lymphoma (DLBCL); key findings from the Phase II MorningSun study (17:30) Case: A man in his mid 50s with relapsed/refractory (R/R) DLBCL receives mosunetuzumab and polatuzumab vedotin in the second-line setting (23:18) Case: A woman in her early 70s with R/R DLBCL receives glofitamab monotherapy in the third-line setting (32:52) Case: A man in his early 80s with R/R DLBCL experiences disease progression after lisocabtagene maraleucel therapy, which was bridged with epcoritamab and gemcitabine/oxaliplatin (37:35) CME information and select publications

Featuring a slide presentation and related discussion from Dr L Elizabeth Budde, including the following topics: Overview of approved and investigational CD20 x CD3 bispecific antibodies (BsAbs) in non-Hodgkin lymphoma; key findings from Phase II studies evaluating glofitamab and epcoritamab in relapsed/refractory (R/R) diffuse large B-cell lymphoma (0:00) Bringing BsAbs into earlier-line settings; key findings from Phase III studies (7:49) Key findings from the Phase III EPCORE DLBCL-1 and EPCORE DLBCL-4 studies and Phase II EPCORE NHL-1 study (14:12) A Phase Ib/II study of glofitamab/polatuzumab in R/R large B-cell lymphoma; investigating the use of BsAbs as front-line therapy and as combination therapy (17:58) Managing treatment-related adverse events; final takeaways (22:53) CME information and select publications

Featuring perspectives from Dr Stephen V Liu and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics: Introduction (0:00) EGFR Mutations (2:23) HER2 Alterations (22:40) Available and Investigational Immunotherapies (32:14) Small Cell Lung Cancer (40:48) CME information and select publications

Featuring an interview with Dr Neeraj Agarwal, including the following topics: Impact of PTEN deficiency on PI3K/AKT/mTOR pathway; optimal approaches to testing (0:00) Approaches to monitoring for disease progression in patients who are PTEN deficient; prognostic significance and implications for testing (7:13) Potential usage of capivasertib as second-line therapy for metastatic androgen pathway modulation-naïve/-sensitive (APMN/S) prostate cancer (15:15) Managing treatment-related adverse events from capivasertib (20:08) Case: A man in his late 50s diagnosed with metastatic APMS prostate cancer and a PTEN deficiency who receives capivasertib (29:17) Case: A man in his late 70s diagnosed with high-volume metastatic APMN prostate cancer and a PTEN deficiency who experiences disease progression on androgen deprivation therapy and enzalutamide (40:39) CME information and select publications

Featuring a slide presentation and related discussion from Dr Neeraj Agarwal, including the following topics: Therapeutic targets of systemic therapy in prostate cancer (0:00) Prevalence of genomic alterations in prostate cancer including PTEN deficiency; prognostic and predictive value (3:52) Optimal timing of and approach to PTEN assessment; pathophysiology surrounding PTEN loss (9:29) Comparison of ipatasertib and capivasertib; key findings from Phase III IPATential150 and CAPItello-281 studies (14:26) Safety and tolerability profile of capivasertib; strategies for management of adverse events (19:21) CME information and select publications

Featuring perspectives from Dr Ann LaCasce and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics: Introduction (0:00) First-Line Treatment (1:33) Bispecific Antibodies and Chimeric Antigen Receptor T-Cell Therapy (20:36) CME information and select publications

Featuring perspectives from Dr Joyce F Liu, Dr David M O'Malley and Dr Brian M Slomovitz, moderated by Dr O'Malley, including the following topics: Case: A woman in her mid 60s with metastatic serous endometrial carcinoma that is HER2 IHC 3+ who received first-line carboplatin/paclitaxel/trastuzumab and second-line trastuzumab deruxtecan — Ursula Matulonis, MD (0:00) Commentary: Role of HER2-directed therapy in the maintenance setting for patients with HER2-positive disease — Professor Jonathan A Ledermann (12:29) CME information and select publications